Studies have shown that these MRAs, while beneficial for reducing cardiovascular mortality and hospitalization, increase the risk of hyperkalemia, particularly in patients with renal dysfunction or those also receiving other renin–angiotensin system inhibitors. The gene discussed is REN; the disease is Abnormal renal physiology.